Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 5/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15964649 | 0.83 | MAP3K14 (0.39) | NR3C2SMN1; SMN2GRM5DAOCREBBP | |
| SCHEMBL3488031 | 0.79 | AHR (0.56) | NR3C2MMP12GRM5PKMDAO | |
| SCHEMBL30609076 | 0.79 | NR3C2 (0.47) | NR3C2MMP12SMN1; SMN2GRM5PARP1 | |
| SCHEMBL17348473 | 0.79 | NR3C2 (0.57) | NR3C2MMP12SMN1; SMN2PKMPARP1 | |
| SCHEMBL1137855 | 0.79 | GRM5 (0.48) | NR3C2MMP12GRM5PARP1ALDH1A1 | |
| SCHEMBL3489518 | 0.79 | NR3C2 (0.47) | NR3C2MMP12GRM5PKMPARP1 | |
| SCHEMBL2483112 | 0.79 | NR3C2 (0.47) | NR3C2MMP12SMN1; SMN2GRM5PARP1 | |
| SCHEMBL3599771 | 0.79 | NR3C2 (0.47) | NR3C2MMP12SMN1; SMN2GRM5PARP1 | |
| SCHEMBL24656095 | 0.78 | NR3C2 (0.47) | NR3C2MMP12SMN1; SMN2GRM5PKM | |
| SCHEMBL8306404 | 0.78 | NR3C2 (0.47) | NR3C2MMP12SMN1; SMN2GRM5PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023280296-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-01-12 | — | — | WO | disclosed |
| WO-2022262736-A1 | BENZOXAZINONE DERIVATIVES | 正大天晴药业集团股份有限公司 | 2022-12-22 | — | — | WO | disclosed |
| CN-115141141-A | Nitrogen-containing heterocyclic derivative with acrylate structure and preparation method thereof | 吉林大学 | 2022-10-04 | — | — | CN | disclosed |
| EP-3279187-B1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3670496-A2 | ACC2 INHIBITORS | Shionogi&Co., Ltd. (JP) | 2020-06-24 | — | — | EP | disclosed |
| US-9522906-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-1370533-B1 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014100730-A1 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ALLERGAN SALES, INC. | 2003-01-30 | — | — | US | disclosed |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ALLERGAN SALES, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002076950-A2 | IMIDIAZOLE DERIVATIVES AND THEIR USE AS AGONISTS SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6329369-B1 | ANALGESICS FOR TREATING GLAUCOMA OR ELEVATED PRESSURE AND OTHER DISEASES WITH REDUCED SIDE EFFECTS BY TREATING A MAMMAL IN NEED THEREOF AN AGONIST OF ALPHA 2B OR ALPHA 2B/2C ADRENERGIC RECEPTOR | ALLERGAN SALES, INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1104407-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan Sales, Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2001000586-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-1036065-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan Sales, Inc. (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028300-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 1999-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023098-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors | ADRA2B, ADRB2, ADRA2C | NR3C2 260/4885MMP12 4522/4885SMN1; SMN2 2593/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | NR3C2 329/4885MMP12 2473/4885SMN1; SMN2 2873/4885 |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | CHRM3, CHRM5, CHRM2 | NR3C2 329/4885MMP12 2473/4885SMN1; SMN2 2873/4885 |
| US-20020156076-A1 | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors | ADRB2, ADRB1, ADRA2B | NR3C2 42/4885MMP12 4755/4885SMN1; SMN2 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.